MEK Mutation
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors (NCT07121829) | Day One Biopharmaceuticals, Inc. | 2022-05-02 |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations (NCT04488003) | BioMed Valley Discoveries, Inc | 2021-01-07 |
Track MEK Mutation automatically
Every clearance here is in the API, with alerts when new ones post.